- Home
- CISS vs ADTX Comparison
CISS vs ADTX Comparison
Compare CISS & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- ADTX
- Stock Information
- Founded
- CISS 2022
- ADTX 2017
- Country
- CISS Greece
- ADTX United States
- Employees
- CISS N/A
- ADTX N/A
- Industry
- CISS Marine Transportation
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- ADTX Health Care
- Exchange
- CISS Nasdaq
- ADTX Nasdaq
- Market Cap
- CISS 2.8M
- ADTX 3.1M
- IPO Year
- CISS N/A
- ADTX 2020
- Fundamental
- Price
- CISS $3.62
- ADTX $1.20
- Analyst Decision
- CISS
- ADTX
- Analyst Count
- CISS 0
- ADTX 0
- Target Price
- CISS N/A
- ADTX N/A
- AVG Volume (30 Days)
- CISS 75.6K
- ADTX 2.0M
- Earning Date
- CISS 08-21-2025
- ADTX 08-18-2025
- Dividend Yield
- CISS N/A
- ADTX N/A
- EPS Growth
- CISS N/A
- ADTX N/A
- EPS
- CISS N/A
- ADTX N/A
- Revenue
- CISS $38,174,754.00
- ADTX $55,323.00
- Revenue This Year
- CISS N/A
- ADTX $15,768.94
- Revenue Next Year
- CISS N/A
- ADTX N/A
- P/E Ratio
- CISS N/A
- ADTX N/A
- Revenue Growth
- CISS N/A
- ADTX N/A
- 52 Week Low
- CISS $2.85
- ADTX $1.05
- 52 Week High
- CISS $23.25
- ADTX $21,400.00
- Technical
- Relative Strength Index (RSI)
- CISS 56.47
- ADTX 39.51
- Support Level
- CISS $3.30
- ADTX $1.13
- Resistance Level
- CISS $3.99
- ADTX $1.30
- Average True Range (ATR)
- CISS 0.20
- ADTX 0.11
- MACD
- CISS 0.05
- ADTX 0.03
- Stochastic Oscillator
- CISS 50.00
- ADTX 46.81
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.